HSP

Investors Still Must Pick Generic Drug Companies By Hand

By Barry Cohen, Health Care Writer
The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.

Apple Bombs, Sectors Revolt — Tuesday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger
Apple records a rare earnings miss after the bell, and Goldman Sachs and IBM misses couldn't hold back financials and techs Tuesday.

7 Pharma Stocks to Sell, STAT

By Louis Navellier, Editor, Growth Investor
Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss.

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

By Barry Cohen, Health Care Writer
Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.

New CEO Tasked with Getting Hospira Back on Track

By Barry Cohen, Health Care Writer
Priorities for Hospira's new CEO include fixing manufacturing problems, launching biosimilars in the U.S.
Load More